Introduction: Alectinib has shown marked efficacy and safety in patients with anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangement-positive NSCLC and a good performance status (PS). It has remained unclear whether alectinib might also be beneficial for such patients with a poor PS.
Introduction
For patients with advanced NSCLC and a poor performance status (PS), especially a PS of 3 or 4, there is no indication for systemic chemotherapy and only palliative care is recommended. 1 Treatment with the EGFR tyrosine kinase inhibitor (TKI) gefitinib, however, showed a durable antitumor effect with tolerable toxicity and a marked improvement in PS in patients with EGFR mutation-positive NSCLC and a poor PS. 2 Alectinib is a potent and selective anaplastic lymphoma kinase (ALK) TKI that has shown excellent antitumor activity with only mild adverse events in patients with NSCLC positivity for anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangement. 3, 4 This drug also manifested pronounced clinical activity in such patients who had progressed while receiving the ALK TKI crizotinib. 5, 6 Although some previous clinical studies of alectinib included subsets of patients with a PS of 2 (w10.0%), 5, 6 most patients enrolled in prior studies of ALK TKIs had a good PS (1) , and it has therefore remained unclear whether such drugs, including alectinib and crizotinib, may also be beneficial for individuals with a poor PS. A phase III trial (JapicCTI-132316) comparing alectinib with crizotinib for the treatment of Japanese patients with ALK rearrangement-positive NSCLC (almost all of whom had a PS of 1) found that adverse events in the alectinib group were much milder than those in the crizotinib group, 7 suggesting that alectinib may be a more suitable treatment option than crizotinib for patients with a poor PS. We have now undertaken a multicenter prospective phase II study to evaluate the efficacy and feasibility of treatment with alectinib for patients with ALK rearrangement-positive NSCLC and a poor PS.
Materials and Methods
Eligible patients had adenocarcinoma of the lung at stage IIIB or IV or postoperative recurrence, tested positive for ALK rearrangement, were at least 20 years old, and had an Eastern Cooperative Oncology Group PS of 2 to 4. Alectinib (300 mg) was administered orally twice a day. The primary end point of the study was objective response rate (ORR). The most informative secondary end point was rate of PS improvement. Further details are provided in the Supplementary Materials and Methods.
Results

Patient Characteristics
From September 2014 to December 2015, a total of 18 patients from 15 institutions were enrolled in the study. Baseline characteristics of the patients are summarized in Table 1 . The median age was 72 years (range 35-84 years), and 10 patients (55.6%) were female. Of the 18 patients, 12 (66.7%), five (27.8%), and one (5.6%) had a PS of 2, 3, or 4, respectively. Fifteen patients (83.3%) had stage IV disease. Nine patients (50.0%) showed brain metastasis, which was untreated in three of these individuals at baseline. ALK rearrangement in tumor samples was demonstrated by immunohistochemistry followed by fluorescence in situ hybridization in 15 patients (83.3%), by reverse transcriptase polymerase chain reaction in two (11.1%), and by fluorescence in situ hybridization alone in one (5.6%). Four patients (22.2%) had undergone treatment with crizotinib. Thirteen patients (72.2%) were both chemotherapy and crizotinib naive.
Efficacy
The median follow-up time for all patients was 9.8 months (range 5.6-18.0 months). Two of the total of 18 patients (11.1%) achieved a complete response, 11 (61.1%) had a partial response, and one (5.6%) achieved stable disease, yielding an ORR of 72.2% (90% confidence interval [CI]: 52.9-85.8%)-which met the primary objective of the study-and a disease control rate of 77.8% (90% CI: 58.7-89.6%) ( Table 2) . A waterfall plot of maximum tumor shrinkage from baseline in 17 patients classified according to PS is shown in Figure 1 ; tumor shrinkage was not evaluable in one patient because of withdrawal of consent before a restaging scan. Sixteen of these 17 patients (94.1%) showed a reduction in tumor size from baseline, with 14 individuals (82.4%) achieving a reduction of 30% or more. Tumor shrinkage of 30% or more was observed in six of six patients with a PS of 3 or higher (100%) and in eight of 11 patients with a PS of 2 (72.7%). The ORRs in patients with a PS of 2 or 3 or higher were 58.3% and 100%, respectively (p ¼ 0.114 [data not shown]), and those in patients with or without a history of crizotinib treatment were 50.0% and 78.6%, respectively (p ¼ 0.533 [data not shown]). The median progression-free survival (PFS) was 10.1 months (95% CI: 7.1-17.8) for all patients ( Fig. 2A) , was better for crizotinib-naive patients than for those who experienced failure of crizotinib treatment (16.2 versus 4.8 months, p < 0.0001) (Fig. 2B) , and did not differ between patients with a PS of 2 and those with a PS of 3 or higher (10.1 and 17.8 months, respectively, p ¼ 0.24) (Fig. 2C) .
The change in PS between baseline and the best score achieved for each patient during treatment is shown in Figure 3 . An improvement in PS was observed in 15 of the 18 patients (83.3%) (90% CI: 64.8-93.1%, p < 0.0001). Such improvement to a PS of 0 or 1, which we considered clinically valuable, was observed in 13 patients (72.2%). All five patients with a low oxygen saturation (< 95%) at baseline experienced an improvement in oxygen saturation up to the normal range (95%) after the initiation of alectinib treatment (see Supplementary Fig. 1 ). Marked intrathoracic tumor shrinkage from baseline (30%) was observed in four of these five patients, with the remaining patient withdrawing consent and therefore being unevaluable for the response to alectinib (data not shown). Such a palliative effect might thus have contributed to the improvement in PS.
Safety
Adverse events reported regardless of cause are shown in Table 3 . No event of grade 4 or higher was recorded, and the incidence of events of grade 3 was low. Although fatigue, appetite loss, nausea, pain, dyspnea, and neurological disorder were relatively common, exacerbation of these adverse events by one grade or more after the initiation of alectinib treatment was infrequent (rates of 22.2%, 5.6%, 16.7%, 0.0%, 0.0%, and 11.1%, respectively), indicating that they were tumor related or influenced by previous treatment. No patient required a dose reduction or withdrawal of alectinib treatment as a result of toxicity. These data thus indicated that the toxicity of treatment with alectinib is low even in patients with a poor PS.
Pharmacokinetics
Given that unfavorable conditions such as a lean body mass and organ dysfunction might give rise to drug overexposure in individuals with a poor PS, we measured the trough concentration of alectinib in plasma of seven patients on day 15. The mean plus or minus SD value was 235 ± 65 ng/mL (see Supplementary Table 1) , which is slightly lower than that measured in patients with a good PS (300 mg twice daily, 355 ± 132 ng/mL [Pharmaceutical and Medical Devices Agency review reports]), supporting the safety of standard-dose alectinib in individuals with a poor PS.
Discussion
ALK rearrangement has been identified in a small subpopulation (2%-5%) of patients with NSCLC. 8 Given that such patients with a poor PS are even rarer, we conducted the present study with the participation of 70 institutions across Japan to achieve the projected accrual goal (n ¼ 17), resulting in the participation of 18 patients from 15 institutions during 18 months. The median age of the patients was 72 years (range 35-84 years), which is older than that previously reported for patients with ALK-rearranged NSCLC. [4] [5] [6] [7] [8] [9] [10] [11] [12] Elderly patients with such disease might be more prone to have a poor PS because of age-associated comorbidities or reduced strength.
The ORR in the present study was 72.2% (90% CI: 52.9-85.8) and the median PFS was 10.1 months (95% CI: 7.1-17.8), with these values being better for crizotinib-naive patients than for those who experienced failure of crizotinib treatment (ORR ¼ 78.6% versus 50.0% [p ¼ 0.533], median PFS ¼ 16.2 versus 4.8 months [p < 0.0001]). Although these effects of alectinib in patients with a poor PS appear to be less pronounced than those previously reported for ALK TKIs in patients with a good PS, [4] [5] [6] [7] [9] [10] [11] [12] the observed clinical benefit of alectinib treatment was much greater than that previously described for chemotherapy or for palliative care alone in patients with a poor PS. 1, 13 The rate of PS improvement was 83.3% (90% CI: 64.8-93.1, p < 0.0001), with the frequency of improvement to a PS of 0 or 1 being 72.2%, indicating that alectinib improved the quality of life for these patients.
In conclusion, our results suggest that alectinib is a treatment option for patients with ALK rearrangementpositive NSCLC and a poor PS, for whom chemotherapy is not indicated. In addition to rearrangements of ALK, other rare driver mutations such as ROS1 and ret protooncogene (RET) rearrangements have also been identified in NSCLC. 14, 15 Prospective studies of the efficacy and safety of corresponding molecularly targeted drugs for patients with such mutations and a poor PS might therefore also be warranted.
